Medical Crossfire®: NTRK Fusions Across Solid Tumors: Toward Harmonization of Pathology and Oncology to Optimize Diagnosis and Management

Medical Crossfire®: NTRK Fusions Across Solid Tumors: Toward Harmonization of Pathology and Oncology to Optimize Diagnosis and Management is organized by Physicians' Education Resource, LLC (PER).

Release Date: February 28, 2020
Expiration Date: February 28, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
NTRK fusions have been identified at low incidence rates in many tumor types and are particularly common in some rare cancers. TRK-specific inhibitors and multikinase inhibitors with efficacy in NTRK-fusion-driven tumors can be highly effective. Identifying which patients to test and understanding the landscape of treatments available is critical to optimizing patient care. However, there is a lack of consensus guidelines on molecular testing, and a multitude of tests are available and in use at different academic centers and commercial laboratories. In this program, the expert panel discusses interpretation of emerging data for NTRK-fusion-driven cancer therapies and testing. This expert perspective on how to apply emerging data can help improve your understanding of the prevalence and treatment of NTRK-fusion-positive tumors.

Benefits of Participating:
• Learn about which tumor types commonly have NTRK fusions and when to test for this alteration
• Gain perspectives on how to appropriately test tumor samples for NTRK fusions
• Identify emerging treatment options to optimize outcomes for patients with NTRK fusions in first-line and later lines of treatment
• Hear expert perspective on how testing for NTRK fusions and TRK-targeted therapies can be integrated into clinical practice

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Assess the prevalence and pathobiology of NTRK fusions across solid tumors and resistance mutations associated with TRK inhibitor therapy
• Identify the challenges and advantages associated with different methods for determining rare molecular alterations in solid tumors for which targeted therapies are available
• Integrate emerging data regarding targeted therapies for NTRK fusions into the context of clinical scenarios for patients with solid tumors
• Formulate a plan of care to identify and manage adverse events associated with the use of TRK targeted therapy in patients with NTRK fusions